Brain natriuretic peptide in pulmonary arterial hypertension: biomarker . . . BNP is a potent vasodilator with mitogenic, hypertrophic and pro-inflammatory properties that is upregulated in pulmonary hypertensive diseases Circulating levels of BNP correlate with mean pulmonary arterial pressure (mPAP) and pulmonary vascular resistance (PVR) in patients with pulmonary arterial hypertension (PAH)
The association of N-terminal pro-brain-type natriuretic peptide with . . . N-terminal pro-brain-type natriuretic peptide (NT-proBNP) is currently used as a surrogate marker for disease severity in pulmonary hypertension (PH) However, NT-proBNP tends to have a high variability and may insufficiently correlate with hemodynamics and exercise capacity
Sendaway capillary NT-proBNP in pulmonary hypertension N-terminal pro-B-type natriuretic peptide (NT-proBNP) is a biomarker of cardiac ventricular wall stress that is incorporated into pulmonary hypertension (PH) risk stratification models Sendaway sampling may enable patients to perform NT-proBNP tests remotely
Pulmonary Hypertension Outcomes Predicted by NT-proBNP N-terminal-pro brain natriuretic peptide (NT-proBNP) was a useful biomarker for both respiratory exacerbations and mortality in infants and young children with pulmonary hypertension according to the results of a study published in Congenital Heart Disease
The Role of NT-proBNP as a Prognostic Marker in Pulmonary Hypertension In an article recently published in CHEST (May 2006), Fijalkowska et al1 provided important information on the value of N-terminal pro-type B natriuretic peptide (NT-proBNP) as a prognostic marker in patients with pulmonary hypertension (PH)